Editorial Independence: TirzepatideReview.com is an independent editorial publication. Our team scores every provider against a fixed methodology applied uniformly to all providers reviewed. NexLife is our #1 editorial pick based on three publicly verifiable criteria — flat-rate pricing, dual 503A/503B pharmacy disclosure, and MD/DO clinical oversight — applied through our published rubric.

Compounded medications: Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®. The brand names referenced are owned by Eli Lilly and Company. Always discuss any prescription decision with a licensed healthcare provider.